Loading...
XTAI
1760
Market cap208mUSD
Jul 14, Last price  
71.30TWD
1D
-0.70%
1Q
5.94%
Jan 2017
5.16%
IPO
283.33%
Name

Panion & BF Biotech Inc

Chart & Performance

D1W1MN
P/E
49.09
P/S
3.01
EPS
1.45
Div Yield, %
2.10%
Shrs. gr., 5y
2.13%
Rev. gr., 5y
5.22%
Revenues
2.03b
+7.85%
559,396,000524,779,000584,249,000674,896,000857,082,0001,014,406,0001,205,065,0001,049,246,0001,212,478,0001,408,741,0001,573,944,0001,568,637,0001,901,211,0002,398,648,0001,881,875,0002,029,645,000
Net income
125m
+61.26%
5,088,000-39,305,000-36,260,000-40,562,00018,149,00048,269,00072,996,00089,720,00090,539,000159,171,000161,329,00027,901,000104,402,000182,345,00077,219,000124,523,000
CFO
351m
+97.94%
76,978,000-13,895,000-36,120,0003,958,00086,225,00076,111,00058,304,000177,217,000113,973,00078,584,00090,984,000-14,555,000401,225,000489,872,000177,418,000351,188,000
Dividend
Jun 13, 20241.5 TWD/sh
Earnings
Aug 11, 2025

Profile

Panion & Bf Biotech Inc., a biotechnology pharmaceutical company, manufactures and sells various pharmaceutical products in Taiwan. The company offers products in the areas of medical beauty, kidney, respiratory tract, gastrointestinal tract, and body and hair cleaning. It also provides oral drugs and topical preparations; hand and mechanical disinfection, body lotion, and skin disinfection products; and pet health products, including surgical and skin prescriptions. Panion & Bf Biotech Inc. was founded in 1976 and is headquartered in Taipei, Taiwan.
URL
https://www.pbf.com.tw/
IPO date
Jun 14, 2004
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,029,645
7.85%
1,881,875
-21.54%
2,398,648
26.16%
Cost of revenue
1,814,469
1,726,098
1,984,606
Unusual Expense (Income)
NOPBT
215,176
155,777
414,042
NOPBT Margin
10.60%
8.28%
17.26%
Operating Taxes
92,912
91,492
151,064
Tax Rate
43.18%
58.73%
36.49%
NOPAT
122,264
64,285
262,978
Net income
124,523
61.26%
77,219
-57.65%
182,345
74.66%
Dividends
(128,609)
(171,478)
(128,609)
Dividend yield
1.81%
1.78%
0.84%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
551,490
580,207
424,634
Long-term debt
173,548
199,699
122,128
Deferred revenue
Other long-term liabilities
30,668
52,527
34,048
Net debt
166,667
177,738
7,408
Cash flow
Cash from operating activities
351,188
177,418
489,872
CAPEX
(185,694)
(181,231)
(198,644)
Cash from investing activities
(158,772)
(155,274)
(144,466)
Cash from financing activities
(170,506)
48,667
(167,388)
FCF
140,846
(45,935)
306,783
Balance
Cash
558,371
534,625
464,257
Long term investments
67,543
75,097
Excess cash
456,889
508,074
419,422
Stockholders' equity
992,373
1,049,673
1,141,419
Invested Capital
2,200,821
2,183,366
2,076,907
ROIC
5.58%
3.02%
12.30%
ROCE
7.88%
5.63%
16.11%
EV
Common stock shares outstanding
86,631
85,791
85,828
Price
82.10
-26.70%
112.00
-37.43%
179.00
138.03%
Market cap
7,112,426
-25.98%
9,608,592
-37.46%
15,363,212
157.83%
EV
7,279,093
9,786,330
15,370,620
EBITDA
379,600
326,167
577,589
EV/EBITDA
19.18
30.00
26.61
Interest
15,022
11,357
7,585
Interest/NOPBT
6.98%
7.29%
1.83%